Concerns about adequate protection from COVID-19 have led to several efforts from chain pharmacies to keep pharmacy staff and employees safe.
Officials with the FDA have approved durvalumab (Imfinzi) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), in combination with standard-of-care (SoC) chemotherapies, in adult patients.
Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data.
Johnson & Johnson expects to initiate human clinical studies for its lead COVID-19 vaccine candidate by September 2020.
Chloroquine and hydroxychloroquine have been authorized to treat hospitalized patients with COVID-19.
Abbott’s ID NOW COVID-19 test is able to deliver results in as little as 5 minutes.
Things to know about the root cause of chickenpox and shingles
Here’s a roundup of the latest coronavirus-related news from this week.
Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
Gilead has now asked the FDA to rescind its orphan drug status for the potential COVID-19 therapy.